XGEVA (Amgen Australia Pty Ltd)
Product name
XGEVA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
161 working days (255)
Active ingredients
denosumab
Registration type
EOI
Indication
XGEVA (solution for injection) is now also indicated for the prevention of skeletal related events in patients with multiple myeloma and in patients with bone metastases from solid tumours.